RBBP7 and inflammatory bowel disease: Furthermore, as current treatments are mostly the biological agent anti-TNF (primarily infliximab) for refractory and severe forms of IBD (Koelink et al., 2020), we verified the m6A phenotype–related hub genes in GSE16879 and found that the therapeutic effect of cluster1 with the lower expression of hub genes, including H2AFZ, NUP37, SNRPD1, CPSF3, and RBBP7, was better than that of cluster2.